Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance  COVID-19 status Phase of research How it helps Latest publication
6D3
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/29/2021
7-Bromo-3-[(7-bromo-4-hydroxy-2-oxo-1H-quinolin-3-yl)methyl]-4-hydroxy-1H-quinolin-2-one
Potential treatment - theoretical effect Experimental Antiviral Sep/14/2020
7-bromo-5-chloro-8-hydroxyquinoline
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/11/2021
7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/02/2021
7-methyl-guanosine-5′-triphosphate-5′-guanosine
Potential treatment - theoretical effect Experimental Antiviral
8-(3-Chlorostyryl)caffeine
Potential treatment - pre-clinical evidence Experimental Antiviral Jul/24/2020
8-{3-hydroxy-4-[(7-hydroxynaphthalen-2-yl)oxy]phenoxy}-1,4-benzodioxin-5-ol
Potential treatment - theoretical effect Experimental Antiviral Apr/25/2021
89C8-ACE2
Potential treatment - pre-clinical evidence Experimental Antiviral Aug/17/2020
9-hexadecenoic acid
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
A-1H4
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-2F1
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
A-2H4
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/27/2021
Abametapir
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
ABBV-744
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
ABP-700
Potential treatment - theoretical effect Experimental Antiviral Nov/06/2020
ABP18
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/14/2021
AC-55541
Potential treatment - theoretical effect Experimental Antiviral Apr/30/2020
Ac-QS5-VS
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/22/2020
AC1MTT7T
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/26/2020
ACE2 1–618-ABD
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/01/2021